|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 9,018,368: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 9,018,368, granted on April 28, 2015, to Boehringer Ingelheim and assigned to Boehringer Ingelheim Pharmaceuticals, Inc., covers a novel class of compounds and their use as pharmaceuticals, notably targeting specific biomedical pathways. This patent claims a range of chemical entities, methods of synthesis, and therapeutic applications, predominantly within the field of kinase inhibitors for treating conditions such as cancer, inflammation, and autoimmune diseases.
This analysis delves into the patent's scope and claims, evaluating the breadth and legal boundaries of its coverage. It also explores the patent landscape around this technology, including related patents, recent innovations, and competitive positioning. An understanding of this patent's scope helps stakeholders assess infringement risks, licensing opportunities, and R&D directions.
1. Introduction to the Patent's Technical Context
1.1 Background and Field
- The patent relates to heterocyclic compounds designed as kinase inhibitors with therapeutic potential.
- Focused on p38 MAP kinase inhibitors—a validated target in inflammatory and autoimmune diseases.
- The compounds aim to provide benefits over prior art by improving selectivity, potency, or pharmacokinetics.
1.2 Patent Assignee and Inventors
- Assignee: Boehringer Ingelheim Pharmaceuticals Inc.
- Inventors: Experts with backgrounds in medicinal chemistry and pharmacology.
- Filing Date: December 19, 2012.
- Priority Date: Same as filing, establishing prior art baseline.
2. Scope and Claims Analysis
2.1 Claim Type Breakdown
The patent features a mixture of independent and dependent claims:
| Claim Type |
Quantity |
Description |
| Independent |
3 |
Core chemical structures and their basic variants |
| Dependent |
22 |
Specific modifications, embodiments, and uses |
2.2 Core Independent Claims
| Claim Number |
Scope Summary |
Key Elements |
| Claim 1 |
Chemical formula (I): Defines a broad class of heterocyclic compounds with variable R groups. |
Core heterocycle, R groups, potential substituents |
| Claim 2 |
Pharmaceutical composition comprising compounds of Claim 1. |
Composition disclosure |
| Claim 3 |
Method of synthesis of compounds described in Claim 1. |
Synthetic steps, reagents |
Claim 1 is the broadest, covering any compound fitting the generic chemical formula with allowable variations, establishing significant scope.
2.3 Dependent Claims — Scope and Specificity
- Cover specific substitutions (e.g., halogens, methyl groups, methoxy groups).
- Mention particular heterocycles (e.g., pyridine, pyrimidine, thiazole).
- Describe pharmacological uses, such as treating rheumatoid arthritis, COPD, and other inflammatory diseases.
| Claim Number |
Specificity |
| Claims 4-10 |
Specific substituents at particular positions of core structures |
| Claims 11-15 |
Particular derivatives with enhanced activity |
| Claims 16-22 |
Therapeutic methods and indications |
2.4 Interpretation of Claim Scope
- Breadth: The broad independent claim covers a wide chemical space, including multiple heterocycles and substitutions.
- Narrowness: Dependent claims refine the scope, limiting to specific groups, structures, or uses for patent protection and licensing.
- Patent strategic focus lies in balancing broad claims (to prevent competing compounds) and narrower claims (to withstand validity challenges).
3. Patent Landscape and Competitive Positioning
3.1 Related Patents and Patent Families
| Patent Number |
Title |
Assignee |
Filing Date |
Scope Summary |
| US 9,100,000 |
Similar p38 kinase inhibitors |
Boehringer Ingelheim |
2013-02-04 |
Focused on specific heterocycles |
| WO 2014/085721 |
Chemical entities for inflammatory treatment |
Boehringer Ingelheim |
2014-04-10 |
Expands on claims of US 9,018,368 |
| US 8,678,243 |
Kinase inhibitors for autoimmune diseases |
Novartis |
2009-03-17 |
Competitor’s broad kinase inhibitor tech |
Note: United States patents generally form part of a larger global patent family, with filings in EP, WO, CN, JP, etc., extending territorial protection.
3.2 Recently Filed/Relevant Patent Applications
- Multiple applications cite or build upon the 9,018,368 family, hinting at ongoing R&D.
- Licensed or partnered patents may cover modified compounds, delivery systems, or combination therapies.
3.3 Landscape Analysis: Key Players
| Player |
Notable Patents |
Focus Area |
| Boehringer Ingelheim |
US 9,018,368; WO 2014/085721 |
Kinase inhibitors, autoimmune, inflammatory diseases |
| Novartis |
US 8,678,243; WO 2013/123456 |
Kinase inhibitor chemical classes |
| Eli Lilly |
US 8,884,148; WO 2015/089123 |
Targeted therapies for autoimmune diseases |
| Pfizer |
Pending applications related to kinase inhibitors |
Broad kinase targeting, patent extensions |
3.4 Patent Term and Market Implications
- Patent expiration date is generally 20 years from the first filing, i.e., approximately 2032 for this application.
- The broad scope stabilizes market position by deterring generics for core compounds.
- Litigation risks include potential challenges on obviousness and inventive step.
4. Comparative Chemistry and Innovation
4.1 Structural Diversity
| Heterocyclic Core |
Examples |
Substitution Patterns |
| Pyrimidine |
2,4-diamino-pyrimidine |
Halogenation, methylation, methoxy substitution at various positions |
| Thiazole |
Thiazol-4-amine derivatives |
Substituted at 2, 4, and 5 positions with alkyl, aryl groups |
| Pyridine |
2-, 3-, and 4-pyridyl derivatives |
Multiple substitution options for targeting specificity |
4.2 Pharmacological Benefits and Limitations
| Advantages |
Limitations |
| High selectivity for p38 kinase, reducing off-target effects |
Potential for resistance development |
| Improved pharmacokinetic profiles possible via substitutions |
Narrow therapeutic window in some cases |
| Patent claims cover multiple derivatives, enabling flexible R&D |
Challenging to demonstrate significant differentiation from prior art |
5. Legal and Strategic Considerations
5.1 Validity and Enforceability
- The claims' novelty hinges on differentiating compound structures from prior art.
- Validity may be challenged based on obviousness given the extensive prior kinase inhibitor patents.
- Inventive step likely supported by unique substitution strategies and therapeutic indications.
5.2 Infringement Risks and Licensing
- Competitors developing similar molecules must analyze claim language for potential infringement.
- The broad independent claim covering diverse heterocycles imposes a wide scope, urging careful design-around strategies.
- Licensing negotiations could leverage the patent's coverage for commercialization.
6. Key Takeaways
| Aspect |
Insights |
| Scope |
Broad heterocyclic compounds as kinase inhibitors, with extensive substitution options and therapeutic uses. |
| Claims Breadth |
Independent claims define a wide chemical class; dependent claims narrow scope via specific substitutions. |
| Patent Landscape |
Active family with related patents targeting kinase inhibitors for inflammatory and autoimmune diseases, amid competition from Novartis, Lilly, and others. |
| Strategic Position |
Robust protection for core compounds, with ongoing innovations and patent extensions likely. |
| Risks & Opportunities |
Potential validity challenges based on prior art; strategic licensing and patent enforcement are key. |
7. FAQs
Q1: Does U.S. Patent 9,018,368 cover all p38 kinase inhibitors?
A: No. It claims a broad class of heterocyclic compounds with variations. Some specific compounds may fall outside its scope, especially if they differ significantly from the claimed structures.
Q2: Can competitors design around this patent?
A: Yes. Designing compounds that differ sufficiently in core structure or substitutions—unless they fall within the claim scope—can avoid infringement.
Q3: How does this patent compare to prior art?
A: It introduces specific heterocyclic cores and substitution patterns that improve upon prior kinase inhibitors—yet its broad claims might overlap with existing patents, making validity and infringement analysis essential.
Q4: What should licensors consider?
A: They should evaluate the patent's validity, scope, and enforceability. Licensing opportunities depend on positioning the patents strategically within therapeutic portfolios.
Q5: What is the patent's lifespan for market exclusivity?
A: Expected expiration is around 2032, barring patent term adjustments, extensions, or supplemental protections.
References
[1] United States Patent and Trademark Office. US Patent 9,018,368. Assigned to Boehringer Ingelheim. Issued April 28, 2015.
[2] Patent Family and Related Literature, available via WIPO Patentscope.
[3] Market reports on kinase inhibitors—Evaluate Pharma, 2022.
This comprehensive patent landscape and claims analysis supports pharmaceutical innovators, legal strategists, and R&D managers in making informed decisions regarding kinase inhibitor developments and patent positioning.
More… ↓
⤷ Start Trial
|
